Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bladder cancer
Biotech
CG Oncology plans IPO ahead of phase 3 bladder cancer readout
Five months after reeling in $105 million from a pre-IPO crossover round, CG Oncology is now ready to take the plunge and go public.
James Waldron
Jan 3, 2024 8:25am
ImmunityBio inks $210M royalty deal to get cancer drug to market
Jan 2, 2024 7:41am
Second layoff wave hits ImmunityBio in less than a year
Sep 22, 2023 11:22am
CG raises $105M crossover round to fund phase 3 cancer trial
Aug 2, 2023 9:07am
Ferring's research site closure signals shift from internal R&D
Apr 11, 2023 11:22am
Spat between Sesen Bio and rival investor group boils over
Jan 26, 2023 10:51am